JP2025069284A5 - - Google Patents
Info
- Publication number
- JP2025069284A5 JP2025069284A5 JP2025013906A JP2025013906A JP2025069284A5 JP 2025069284 A5 JP2025069284 A5 JP 2025069284A5 JP 2025013906 A JP2025013906 A JP 2025013906A JP 2025013906 A JP2025013906 A JP 2025013906A JP 2025069284 A5 JP2025069284 A5 JP 2025069284A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921015050 | 2019-04-15 | ||
| IN201921015050 | 2019-04-15 | ||
| IN202021004422 | 2020-01-31 | ||
| IN202021004422 | 2020-01-31 | ||
| PCT/IB2020/053565 WO2020212874A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
| JP2021561000A JP7628962B2 (ja) | 2019-04-15 | 2020-04-15 | 乾癬性関節炎に罹患している対象者の治療方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561000A Division JP7628962B2 (ja) | 2019-04-15 | 2020-04-15 | 乾癬性関節炎に罹患している対象者の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025069284A JP2025069284A (ja) | 2025-04-30 |
| JP2025069284A5 true JP2025069284A5 (https=) | 2025-10-17 |
Family
ID=72837755
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561000A Active JP7628962B2 (ja) | 2019-04-15 | 2020-04-15 | 乾癬性関節炎に罹患している対象者の治療方法 |
| JP2025013906A Pending JP2025069284A (ja) | 2019-04-15 | 2025-01-30 | 乾癬性関節炎に罹患している対象者の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561000A Active JP7628962B2 (ja) | 2019-04-15 | 2020-04-15 | 乾癬性関節炎に罹患している対象者の治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220298233A1 (https=) |
| EP (1) | EP3956357A4 (https=) |
| JP (2) | JP7628962B2 (https=) |
| KR (1) | KR20210140780A (https=) |
| CN (1) | CN113825768A (https=) |
| AU (1) | AU2020259375A1 (https=) |
| BR (1) | BR112021020612A2 (https=) |
| CA (1) | CA3143604A1 (https=) |
| IL (1) | IL287213A (https=) |
| JO (1) | JOP20210279A1 (https=) |
| MA (1) | MA55729A (https=) |
| MX (1) | MX2021012652A (https=) |
| MY (1) | MY210310A (https=) |
| PH (1) | PH12021552536A1 (https=) |
| SG (1) | SG11202111056YA (https=) |
| WO (1) | WO2020212874A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024323792A1 (en) * | 2023-08-11 | 2026-03-12 | Innovent Biologics (Suzhou) Co., Ltd. | Method for treating plaque psoriasis wherein subject previously receiving biologic therapy for plaque psoriasis switches to using anti-il23p19 antibody |
| AU2024338774A1 (en) * | 2023-09-07 | 2026-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Method for treating moderate and severe psoriasis using recombinant anti-il-23p19 antibody |
| WO2026069253A1 (en) * | 2024-09-30 | 2026-04-02 | Sun Pharmaceutical Industries Limited | Long term safety of tildrakizumab in psoriatic arthritis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| EP2007426A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
| AR065420A1 (es) * | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
| CA2734919C (en) * | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| ES2729603T3 (es) * | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
-
2020
- 2020-04-15 WO PCT/IB2020/053565 patent/WO2020212874A1/en not_active Ceased
- 2020-04-15 MX MX2021012652A patent/MX2021012652A/es unknown
- 2020-04-15 KR KR1020217037137A patent/KR20210140780A/ko active Pending
- 2020-04-15 EP EP20790874.0A patent/EP3956357A4/en active Pending
- 2020-04-15 JP JP2021561000A patent/JP7628962B2/ja active Active
- 2020-04-15 PH PH1/2021/552536A patent/PH12021552536A1/en unknown
- 2020-04-15 AU AU2020259375A patent/AU2020259375A1/en active Pending
- 2020-04-15 CN CN202080029205.6A patent/CN113825768A/zh active Pending
- 2020-04-15 CA CA3143604A patent/CA3143604A1/en active Pending
- 2020-04-15 BR BR112021020612A patent/BR112021020612A2/pt unknown
- 2020-04-15 US US17/603,921 patent/US20220298233A1/en active Pending
- 2020-04-15 MA MA055729A patent/MA55729A/fr unknown
- 2020-04-15 MY MYPI2021005910A patent/MY210310A/en unknown
- 2020-04-15 SG SG11202111056YA patent/SG11202111056YA/en unknown
-
2021
- 2021-10-12 IL IL287213A patent/IL287213A/en unknown
- 2021-10-14 JO JOP/2021/0279A patent/JOP20210279A1/ar unknown
-
2025
- 2025-01-30 JP JP2025013906A patent/JP2025069284A/ja active Pending